Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア（Wikipedia）』「2015/11/08 17:45:57」(JST)

wiki en

Beraprost is a synthetic analogue of prostacyclin, under clinical trial for the treatment of pulmonary hypertension. It is also being studied for use in avoiding reperfusion injury.

Clinical pharmacology

As an analogue of prostacyclin PGI₂, beraprost affects vasodilation, which in turn lowers blood pressure. Beraprost also inhibits platelet aggregation, though the role this phenomenon may play in relation to pulmonary hypertension has yet to be determined.

Dosage and administration

Beraprost is administered orally as a pill available in strength of 20 mcg. Dose ranges from 60 to 180 mcg in divided doses after meals.

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

1. 下肢末梢動脈疾患の症状を治療するための試験的治療 investigational therapies for treating symptoms of lower extremity peripheral artery disease
2. 間質性肺疾患関連の肺高血圧症 pulmonary hypertension associated with interstitial lung disease
3. 初期治療に抵抗性を示したレイノー現象の治療 treatment of the raynaud phenomenon resistant to initial therapy
4. 跛行のマネージメント management of claudication
5. 成人における全身性硬化症（強皮症）の治療および予後の概要 overview of the treatment and prognosis of systemic sclerosis scleroderma in adults

Japanese Journal

Effects of beraprost sodium, an oral prostacyclin analog, on insulin resistance in patients with type 2 diabetes

Diabetology international 6(1), 39-45, 2015
NAID 40020406077

小児期肺動脈性高血圧の正しく的確な治療戦略

日本小児循環器学会雑誌 31(4), 157-183, 2015
NAID 130005098178

Beraprost Sodium Protects Against Diabetic Nephropathy in Patients with Arteriosclerosis Obliterans: A Prospective, Randomized, Open-label Study

Journal of Nippon Medical School 82(2), 84-91, 2015
NAID 130005068457

Related Pictures

★リンクテーブル★

リンク元	「ベラプロスト」
拡張検索	「beraprost sodium」

「ベラプロスト」

Beraprost
Systematic (IUPAC) name
	2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-; methyl-1-octen-6-ynyl)-1H-cyclopenta(b)benzofuran-; 5-butanoic acid
Clinical data
AHFS/Drugs.com	International Drug Names
Legal status	?;
Routes of; administration	Oral
Pharmacokinetic data
Bioavailability	50–70%
Metabolism	Unknown
Biological half-life	35–40 minutes
Excretion	?
Identifiers
CAS Registry Number	88430-50-6 88475-69-8
ATC code	B01AC19
PubChem	CID: 5282428
IUPHAR/BPS	1967
ChemSpider	5293169
UNII	35E3NJJ4O6
ChEMBL	CHEMBL1207745
Chemical data
Formula	C24H30O5
Molecular mass	398.492 g/mol
	InChI InChI=1S/C24H30O5/c1-3-4-7-15(2)19(25)13-12-17-20(26)14-21-23(17)18-10-5-8-16(24(18)29-21)9-6-11-22(27)28/h5,8,10,12-13,15,17,19-21,23,25-26H,6-7,9,11,14H2,1-2H3,(H,27,28)/b13-12+/t15?,17-,19+,20+,21-,23-/m0/s1 ; Key:CTPOHARTNNSRSR-APJZLKAGSA-N ;
(what is this?) (verify)